Kiromic BioPharma Inc

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell therapies with a therapeutic focus on immuno-oncology. Kiromic Biopharma is the only cell therapy company combining genetically edited Gamma Delta CAR-T (GD CAR-T) cells with proprietary targeting technology to address solid malignancies.

Kiromic is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline.

The pipeline development is leveraged through the Company’s proprietary target discovery engine called DIAMOND AITM. Kiromic's DIAMOND AITM is where data science meets target identification to dramatically compress the years and millions of dollars required to develop a cellular therapeutic.

Cancer cells will down regulate or shed targets in order to avoid detection and destruction by T-cells (the immune system).
Alternative protein sequences, called “isoforms’, are generally much harder for tumors to hide from the immune system.
Target isoforms are protein variants of the same targets and include variations in the primary amino acid sequence that can change the final folded form of the target, increasing its ability to be recognized by T-cells.

To detect isoforms, Diamond shows a box plot of the expression of unique cancer targets such as target isoforms which are detected in the cancer genome tissue atlas, which are then correlated with a box plot of the matching isoforms in normal genotype-tissue expression data sets. Diamond then highlights the normal sequence of amino acids that are specific for the selected cancer isoforms.